Global News and Digital Insights
for the Healthcare Industry

Pfizer’s Xalkori for ALK-positive tumors bags FDA’s approval

Pfizer Xalkori, an oral medication for patients suffering from anaplastic lymphoma kinase (ALK) positive lung cancer, has received second nod of approval by the US Food and Drug Administration. The drug is now being used for the treatment of other types of ALK-positive disorders as well. Xalkori gets approval for the treatment of patients in which tumour keeps growing and cannot be eradicated with the help of surgery. The good news came 18 months after Xalkori gained FDA’s nod for a rare form of non-Hodgkin lymphoma.

Read More from FiercePharma

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn